Corrigendum to "The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies" [Vaccine 30 (2012) 886-892] DOI: 10.1016/j.vaccine.2011.11.104;The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies

Vaccine

Volumn 30, Issue 5, 2012, Pages 886-892

  Ambrose, Christopher S ^a   Wu, Xionghua ^a   Knuf, Markus ^b,c   Wutzler, Peter ^d  

^a MEDIMMUNE   (United States)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Child; Influenza vaccine; Live attenuated influenza vaccine; Meta analysis; Trivalent inactivated influenza vaccine; Vaccine efficacy

Indexed keywords

INFLUENZA VACCINE; PLACEBO;

ADOLESCENT; ARTICLE; CHILD; EUROPE; HUMAN; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; META ANALYSIS; MIDDLE EAST; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHOOL CHILD; SEX DIFFERENCE; UNITED STATES;

EID: 84855430375     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.083     Document Type: Erratum

References (30)

1. World Health Organization Influenza. [accessed 18.05.11]. http://www.who.int/immunization/topics/influenza/en/index.html.
2. World Health Organization Influenza (seasonal). Fact sheet No. 211. [accessed 12.05.11]. http://www.who.int/mediacentre/factsheets/fs211/en/index.html.
3. Heikkinen T., Silvennoinen H., Peltola V., Ziegler T., Vainionpaa R., Vuorinen T., et al. Burden of influenza in children in the community. J Infect Dis 2004, 190:1369-1373.
4. Longini I.M., Halloran M.E. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005, 161:303-306.
5. McIntosh K., Lieu T. Is it time to give influenza vaccine to healthy infants. N Engl J Med 2000, 342:275-276.
6. Reichert T.A., Sugaya N., Fedson D.S., Glezen W.P., Simonsen L., Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001, 344:889-896.
7. Neuzil K.M., Zhu Y., Griffin M.R., Edwards K.M., Thompson J.M., Tollefson S.J., et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002, 185:147-152.
8. Piedra P.A., Gaglani M.J., Kozinetz C.A., Herschler G., Riggs M., Griffith M., et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005, 23:1540-1548.
9. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000, 136:168-175.
10. Lum L.C., Borja-Tabora C.F., Breiman R.F., Vesikari T., Sablan B.P., Chay O.M., et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2010, 28:1566-1574.
11. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338:1405-1412.
12. Bracco Neto H., Farhat C.K., Tregnaghi M.W., Madhi S.A., Razmpour A., Palladino G., et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009, 28:365-371.
13. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
14. Tam J.S., Capeding M.R., Lum L.C., Chotpitayasunondh T., Jiang Z., Huang L.M., et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007, 26:619-628.
15. Vesikari T., Fleming D.M., Aristegui J.F., Vertruyen A., Ashkenazi S., Rappaport R., et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006, 118:2298-2312.
16. Ashkenazi S., Vertruyen A., Aristegui J., Esposito S., McKeith D.D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
17. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
18. Fleming D.M., Crovari P., Wahn U., Klemola T., Schlesinger Y., Langussis A., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25:860-869.
19. Rhorer J., Ambrose C.S., Dickinson S., Hamilton H., Oleka N.A., Malinoski F.J., et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009, 27:1101-1110.
20. Belshe R.B., Coelingh K., Ambrose C.S., Woo J.C., Wu X. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010, 28:2149-2156.
21. Whitehead A. Meta-analysis of controlled clinical trials 2002, John Wiley & Sons, Chichester, NY.
22. Cochran W. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
23. Rota P.A., Wallis T.R., Harmon M.W., Rota J.S., Kendal A.P., Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 1990, 175:59-68.
24. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010, 28(Suppl. 4):D45-D53.
25. Piedra P.A., Gaglani M.J., Kozinetz C.A., Herschler G.B., Fewlass C., Harvey D., et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007, 120:e553-e564.
26. Ambrose C.S., Yi T., Walker R.E., Connor E.M. Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J 2008, 27:744-748.
27. Belshe R.B., Ambrose C., Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008, 26:D10-D16.
28. Belshe R.B., Toback S.L., Yi T., Ambrose C.S. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respi Viruses 2010, 4:141-145.
29. Block S.L., Heikkinen T., Toback S.L., Zheng W., Ambrose C.S. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children. Pediatr Infect Dis J 2011, 30:203-207.
30. Follmann D.A., Proschan M.A. Valid inference in random effects meta-analysis. Biometrics 1999, 55:732-737.